These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 24646282)

  • 1. From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?
    Flaten V; Laurent C; Coelho JE; Sandau U; Batalha VL; Burnouf S; Hamdane M; Humez S; Boison D; Lopes LV; Buée L; Blum D
    Biochem Soc Trans; 2014 Apr; 42(2):587-92. PubMed ID: 24646282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purinergic receptors as potential therapeutic targets in Alzheimer's disease.
    Woods LT; Ajit D; Camden JM; Erb L; Weisman GA
    Neuropharmacology; 2016 May; 104():169-79. PubMed ID: 26519903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A
    Merighi S; Borea PA; Varani K; Vincenzi F; Jacobson KA; Gessi S
    Curr Med Chem; 2022; 29(24):4138-4151. PubMed ID: 34844537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies.
    Takahashi RN; Pamplona FA; Prediger RD
    Front Biosci; 2008 Jan; 13():2614-32. PubMed ID: 17981738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review.
    Rivera-Oliver M; Díaz-Ríos M
    Life Sci; 2014 Apr; 101(1-2):1-9. PubMed ID: 24530739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Purinergic signaling in Alzheimer's disease.
    Erb L; Woods LT; Khalafalla MG; Weisman GA
    Brain Res Bull; 2019 Sep; 151():25-37. PubMed ID: 30472151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeine for Prevention of Alzheimer's Disease: Is the A
    Merighi S; Travagli A; Nigro M; Pasquini S; Cappello M; Contri C; Varani K; Vincenzi F; Borea PA; Gessi S
    Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production.
    Arendash GW; Schleif W; Rezai-Zadeh K; Jackson EK; Zacharia LC; Cracchiolo JR; Shippy D; Tan J
    Neuroscience; 2006 Nov; 142(4):941-52. PubMed ID: 16938404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease.
    Cellai L; Carvalho K; Faivre E; Deleau A; Vieau D; Buée L; Blum D; Mériaux C; Gomez-Murcia V
    Front Neurosci; 2018; 12():520. PubMed ID: 30123104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenosine receptors and caffeine in retinopathy of prematurity.
    Chen JF; Zhang S; Zhou R; Lin Z; Cai X; Lin J; Huo Y; Liu X
    Mol Aspects Med; 2017 Jun; 55():118-125. PubMed ID: 28088487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators.
    Pan L; Ma Y; Li Y; Wu H; Huang R; Cai Z; Wu X
    Mini Rev Med Chem; 2021; 21(11):1288-1302. PubMed ID: 33302833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adenosine receptors and Huntington's disease.
    Lee CF; Chern Y
    Int Rev Neurobiol; 2014; 119():195-232. PubMed ID: 25175968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Caffeine, adenosine receptors, memory and Alzheimer disease].
    Cunha RA
    Med Clin (Barc); 2008 Dec; 131(20):790-5. PubMed ID: 19094882
    [No Abstract]   [Full Text] [Related]  

  • 14. The Medicinal Chemistry of Caffeine.
    Faudone G; Arifi S; Merk D
    J Med Chem; 2021 Jun; 64(11):7156-7178. PubMed ID: 34019396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of methylxanthines and adenosine receptors on neurodegeneration: human and experimental studies.
    Chen JF; Chern Y
    Handb Exp Pharmacol; 2011; (200):267-310. PubMed ID: 20859800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ostracising caffeine from the pharmacological arsenal for attention-deficit hyperactivity disorder--was this a correct decision? A literature review.
    Ioannidis K; Chamberlain SR; Müller U
    J Psychopharmacol; 2014 Sep; 28(9):830-6. PubMed ID: 24989644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine receptor signalling in Alzheimer's disease.
    Trinh PNH; Baltos JA; Hellyer SD; May LT; Gregory KJ
    Purinergic Signal; 2022 Sep; 18(3):359-381. PubMed ID: 35870032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adenosine receptor affinities and monoamine oxidase B inhibitory properties of sulfanylphthalimide analogues.
    Van der Walt MM; Terre'Blanche G; Petzer A; Petzer JP
    Bioorg Chem; 2015 Apr; 59():117-23. PubMed ID: 25746740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of adenosine receptor signaling.
    Peleli M; Fredholm BB; Sobrevia L; Carlström M
    Mol Aspects Med; 2017 Jun; 55():4-8. PubMed ID: 28088486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Neuroprotective Effects of Moderate and Regular Caffeine Consumption in Alzheimer's Disease.
    Zhou X; Zhang L
    Oxid Med Cell Longev; 2021; 2021():5568011. PubMed ID: 34447487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.